The COVID-19 Effect: Medicare Part B Oncology Drug Claims Down 40% Through April
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.